Hereditary Oncology Testing: Wei Shen, Ph.D.
Wei Shen, Ph.D., discusses Mayo Clinic Laboratories’ new hereditary oncology panels, which use next-generation sequencing to identify germline alterations associated with increased cancer risk. Curated through a rigorous selection framework developed by M
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
(00:32):
But before we get started, Dr. Shen, could you provide us with a little bit about you and your background?
(01:15):
So why don't we start our discussion today with having you give us a brief overview of these new hereditary oncology panels.
(03:56):
Can you tell us which patients should have this type of testing and when it should be performed?
(05:31):
Do you want to talk about what other test options are available and how our testing is different or how it compares to this other testing?
(06:51):
So then the last question I have for you today, and maybe the most important is how are these results used in patient care?